Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2022 · 10-Q
Revenue$11.26B$11.26B+10.1% vs Q2 2021 Net Income$2.02B$2.02B+69.7% vs Q2 2021 EPS Diluted$1.14$1.14+72.7% vs Q2 2021 Operating Income$2,376,000,000+70.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,031,000,000+18.4% Margins · derivedOperating margin21.1%+7.5 pt vs Q2 2021
Net margin17.9%+6.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 2, 2022 · 33 d after period end